Compile Data Set for Download or QSAR
Report error Found 47 Enz. Inhib. hit(s) with all data for entry = 2406
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364420(US9862688, Compound 6)
Affinity DataIC50: 1.64nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364420(US9862688, Compound 6)
Affinity DataIC50: 3.86nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364418(US9862688, Compound 5)
Affinity DataIC50: 4.90nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364420(US9862688, Compound 6)
Affinity DataIC50: 5.90nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364422(US9862688, Compound 7)
Affinity DataIC50: 6.80nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364417(US9862688, Compound 4)
Affinity DataIC50: 7.95nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364410(US9862688, Compound 3)
Affinity DataIC50: 12.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364420(US9862688, Compound 6)
Affinity DataIC50: 38nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364403(US9862688, Compound 2)
Affinity DataIC50: 45nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364373(US9862688, Compound 1)
Affinity DataIC50: 55.5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364417(US9862688, Compound 4)
Affinity DataIC50: 64.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364410(US9862688, Compound 3)
Affinity DataIC50: 72.7nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364418(US9862688, Compound 5)
Affinity DataIC50: 94nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364422(US9862688, Compound 7)
Affinity DataIC50: 105nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364417(US9862688, Compound 4)
Affinity DataIC50: 252nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364417(US9862688, Compound 4)
Affinity DataIC50: 372nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364403(US9862688, Compound 2)
Affinity DataIC50: 382nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364417(US9862688, Compound 4)
Affinity DataIC50: 415nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364373(US9862688, Compound 1)
Affinity DataIC50: 482nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364410(US9862688, Compound 3)
Affinity DataIC50: 542nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364417(US9862688, Compound 4)
Affinity DataIC50: 623nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364418(US9862688, Compound 5)
Affinity DataIC50: 676nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364422(US9862688, Compound 7)
Affinity DataIC50: 794nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364422(US9862688, Compound 7)
Affinity DataIC50: 954nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364418(US9862688, Compound 5)
Affinity DataIC50: 1.11E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364410(US9862688, Compound 3)
Affinity DataIC50: 1.12E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364410(US9862688, Compound 3)
Affinity DataIC50: 1.22E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364418(US9862688, Compound 5)
Affinity DataIC50: 1.37E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364422(US9862688, Compound 7)
Affinity DataIC50: 1.44E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364403(US9862688, Compound 2)
Affinity DataIC50: 1.82E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364418(US9862688, Compound 5)
Affinity DataIC50: 1.97E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364420(US9862688, Compound 6)
Affinity DataIC50: 2.08E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364410(US9862688, Compound 3)
Affinity DataIC50: 2.26E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364422(US9862688, Compound 7)
Affinity DataIC50: 2.28E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364373(US9862688, Compound 1)
Affinity DataIC50: 2.99E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364403(US9862688, Compound 2)
Affinity DataIC50: 3.04E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364403(US9862688, Compound 2)
Affinity DataIC50: 3.11E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364420(US9862688, Compound 6)
Affinity DataIC50: 3.18E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364403(US9862688, Compound 2)
Affinity DataIC50: 3.35E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364373(US9862688, Compound 1)
Affinity DataIC50: 4.04E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase ABL1(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364373(US9862688, Compound 1)
Affinity DataIC50: 7.95E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364373(US9862688, Compound 1)
Affinity DataIC50: 8.34E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetUMP-CMP kinase(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364417(US9862688, Compound 4)
Affinity DataIC50: 3.80E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetZinc finger protein GLIS2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364403(US9862688, Compound 2)
Affinity DataIC50: 1.93E+5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetUMP-CMP kinase(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364403(US9862688, Compound 2)
Affinity DataIC50: 2.73E+5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetUMP-CMP kinase(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364410(US9862688, Compound 3)
Affinity DataIC50: 4.90E+5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent

TargetUMP-CMP kinase(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM364373(US9862688, Compound 1)
Affinity DataIC50: 7.26E+5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting JAK3 and other kinases were obtained using an INVITROGEN Select Screening assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/3/2019
Entry Details
US Patent